Novel Hydrophilic Taxane Analogues inhibit Growth of Cancer Cells

Abstract

In our era there has been several anti-cancer drugs which have undergone both experimental and clinical trials; however, due to their poor solubilities, numerous side effects, insufficient bioavailability and poor compliance, many have resulted into poor outcomes. Therefore, our aim was to investigate the effects of novel hydrophilic taxanes analogues CQMU-0517 and CQMU-0519 on growth of A549 lung, SKVO3 ovary and MCF7 breast carcinoma cell lines. Different concentrations of original paclitaxel, CQMU-0517, original docetaxel and CQMU-0519 were utilized on three cell lines, where cell growth was assessed using cell culture kit-8 and flow cytometry analysis. The results unveiled that CQMU-0517 and CQMU-0519 suppressed cell growth in the three particular cell lines, cell cycle arrest being evident in the G2/M phase. Hence, the results showed that these new taxane analogues have potential and warrant future clinical trials.

Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB/BBTB models

“…GB is the most common primary malignant brain tumour among the adult population, making up 46% of all the malignant brain and central nervous system tumours and 15% of all primary brain tumours [2]. Docetaxel (DTX) has shown profound benefits in the treatment of various types of cancers (breast, head and neck, prostate, and gastric carcinoma) [3,4], with the commercial dosage form Taxotere® licensed by Sanofi-Aventis and approved by the FDA [5]. Though DTX has shown to successfully inhibit brain tumour growth following local injection in a mouse brain tumour model [6], it has not been applied to treat brain metastases or primary tumours as it is subject to P-glycoprotein (P-gp) efflux at the blood-brain barrier (BBB) and consequently is unable to accumulate in the brain at adequate concentrations required for tumour regression [7].…”

Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles

“…For instance, two new hydrophilic anti-cancer drugs, CQMU-0517 and CQMU-0519, were synthesized and studied on antitumor activities in vitro (Henni-Silhadi et al, 2007;Fauzee et al, 2012).…”